Livzon Pharmaceutical Group Inc.
1513.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$27.08B
Close$
Share Statistics
| Market cap | $27.08 Billion |
|---|---|
| Enterprise Value | $23.95 Billion |
| Dividend Yield | $1.64 (4.69%) |
| Earnings per Share | $2.27 |
| Beta | 0.24 |
| Outstanding Shares | 887,907,171 |
Return
| Return on Equity | 12.44% |
|---|---|
| Return on Assets | 7.05% |
| Return on Invested Capital | 14.56% |
Valuation & Multiples
| P/E Ratio | 16.14 |
|---|---|
| PEG | -35.79 |
| Price to Sales | 1.77 |
| Price to Book Ratio | 1.33 |
| Enterprise Value to Revenue | 2.25 |
| Enterprise Value to EBIT | 10.87 |
| Enterprise Value to Net Income | 14 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 0.32 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 21, 2026
EPS Estimate
$0.74
Average shareholder expectationRevenue Estimate
$3.41 B
Average shareholder expectationNext Earnings Call
Expected Date
October 23, 2026
EPS Estimate
$0.56
Average shareholder expectationRevenue Estimate
$3.00 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Livzon Pharmaceutical Group Inc.
8,878 employees
CEO: Daping Liu Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturin...